Inhalation Sciences Sweden AB (publ) (XSAT:ISAB)
Sweden · Delayed Price · Currency is SEK 0.1425
+0.0025 (1.79%)
At close: Aug 26, 2026
XSAT:ISAB Income Statement
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 8.3 | 3.04 | 11.05 | 17.5 | 12.19 | 9.42 | |
Revenue Growth | 54.96% | -72.47% | -36.89% | 43.55% | 29.42% | -7.05% |
Cost of Revenue | 2.97 | 0.46 | 0.94 | 3.54 | 2.55 | 4.2 |
Gross Profit | 5.33 | 2.59 | 10.11 | 13.96 | 9.64 | 5.22 |
Selling, General & Admin | 9.93 | 8.61 | 8.96 | 11.08 | 13.18 | 11.88 |
Research & Development | 4.02 | 4.15 | 6.74 | 7.12 | 8.84 | 9.93 |
Other Operating Expenses | -0.06 | -0.02 | -0.52 | -0.48 | -0.35 | -0.02 |
Operating Expenses | 13.89 | 12.74 | 15.19 | 17.72 | 21.67 | 21.79 |
Operating Income | -8.57 | -10.16 | -5.08 | -3.76 | -12.03 | -16.57 |
Interest Expense | -0 | -0.01 | -0.08 | -1 | -0.1 | -0.04 |
Interest & Investment Income | 0.01 | 0.01 | 0.01 | 0.01 | 0 | - |
Other Non Operating Income (Expenses) | - | - | - | - | -0 | - |
EBT Excluding Unusual Items | -8.56 | -10.16 | -5.15 | -4.74 | -12.13 | -16.61 |
Pretax Income | -8.56 | -10.16 | -5.15 | -4.74 | -12.13 | -16.61 |
Net Income | -8.56 | -10.16 | -5.15 | -4.74 | -12.13 | -16.61 |
Net Income to Common | -8.56 | -10.16 | -5.15 | -4.74 | -12.13 | -16.61 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 43 | 29 | 15 | 13 | 11 | 10 |
Shares Outstanding (Diluted) | 43 | 29 | 15 | 13 | 11 | 10 |
Shares Change | 154.87% | 91.72% | 14.29% | 16.67% | 12.02% | 16.82% |
EPS (Basic) | -0.20 | -0.35 | -0.34 | -0.36 | -1.07 | -1.64 |
EPS (Diluted) | -0.20 | -0.35 | -0.34 | -0.36 | -1.07 | -1.64 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -9.86 | -10.79 | -2.94 | -3.74 | -12.05 | -18.89 |
Free Cash Flow Per Share | -0.23 | -0.37 | -0.19 | -0.28 | -1.06 | -1.86 |
Gross Margin | 64.20% | 85.00% | 91.52% | 79.77% | 79.08% | 55.40% |
Operating Margin | -103.23% | -333.94% | -45.95% | -21.46% | -98.61% | -175.88% |
Profit Margin | -103.11% | -334.10% | -46.59% | -27.10% | -99.43% | -176.28% |
Free Cash Flow Margin | -118.84% | -354.69% | -26.59% | -21.38% | -98.79% | -200.52% |
EBITDA | -8.54 | -10.04 | -4.94 | -3.57 | -11.78 | -16.33 |
EBITDA Margin | -102.92% | - | -44.69% | -20.39% | -96.60% | -173.27% |
D&A For EBITDA | 0.03 | 0.11 | 0.14 | 0.19 | 0.25 | 0.25 |
EBIT | -8.57 | -10.16 | -5.08 | -3.76 | -12.03 | -16.57 |
EBIT Margin | -103.23% | - | -45.95% | -21.46% | -98.61% | -175.88% |